Sanofi

Sanofi S.A.

Formerly	Sanofi-Synthélabo (1999–2004) Sanofi-Aventis (2004–2011)
Company type	Public
Traded as	Euronext Paris: SAN Nasdaq: SNY CAC 40 component
ISIN	FR0000120578
Industry	Pharmaceuticals Biotechnology Healthcare
Founded	15 February 1973; 51 years ago (1973-02-15)
Headquarters	Paris, France
Area served	Worldwide
Key people	Serge Weinberg (chairman) Paul Hudson (CEO)
Products	Medications, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...)
Revenue	€43.07 billion (2023)
Operating income	€7.875 billion (2023)
Net income	€5.436 billion (2023)
Total assets	€126.4 billion (2023)
Total equity	€74.35 billion (2023)
Number of employees	86,088 (2023)
Subsidiaries	Sanofi Pasteur Genzyme Shantha Biotechnics Chattem Ablynx Bioverativ
Website	sanofi.com
Footnotes / references [1]

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.^[2] In 2023, the company’s seat in Forbes Global 2000 was 89.^[3]

Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the last through its subsidiary Sanofi Pasteur).^[4]